Please login to the form below
influenza
This page shows the latest influenza news and features for those working in and with pharma, biotech and healthcare.
UK COVID-19 vaccine ‘challenge trials’ could intentionally infect participants with virus
In the past, this type of trial has been used to investigate a range of diseases, including influenza, malaria, typhoid, dengue fever and cholera.
Latest news
-
Roche plans to launch rapid COVID-19 antigen test later this month
The Winterplex test includes two gene targets specific to COVID-19, as well as gene targets for influenza A and B and respiratory syncytial virus (RSV).
-
Novacyt launches diagnostic test to differentiate between COVID-19 and flu
The clinical diagnostics company said that its Winterplex test includes two gene targets specific to COVID-19, as well as gene targets for influenza A and B and respiratory syncytial virus
-
US secures 100 million doses of Sanofi/GSK’s COVID-19 vaccine
The vaccine candidate is based on Sanofi’s recombinant protein technology, used to produce its influenza vaccine, and GSK’s established pandemic adjuvant technology.
-
Medicago doses first patients with plant-derived COVID-19 vaccine
Medicago has already completed a phase 3 clinical trial of a quadrivalent VLP influenza vaccine candidate and phase 2 clinical trials of a H1N1 pandemic vaccine candidate, both using its
-
France’s Osivax raises over €30m for universal flu and coronavirus vaccines
French biotech company Osivax has received over 30m in public funding for the development of innovative universal vaccines targeting the novel coronavirus and influenza. ... Similar to influenza, which leads to regular global outbreaks, COVID-19 has the
More from news
Approximately 16 fully matching, plus 199 partially matching documents found.
Latest Intelligence
-
Effectively communicating in a public health crisis
In John M Barry’s 2009 Nature essay titled Pandemics: Avoiding the Mistakes of 1918, he said: ‘In the next influenza pandemic.
-
Biotech profile: Tom Evans, CEO, Vaccitech.
What are the shortcomings of current influenza vaccines, and why are new products needed? ... The outcome measurement is to decrease the amount of laboratory-confirmed influenza illness.
-
Case study: Break the flu cycle
76% of delegates felt more confident in their ability to manage the influenza vaccination. ... influenza infection, particularly among the more at-risk group of 65 years and over.
-
Deal Watch February 2016
coli and influenza, and in toxicology applications. While Abbott already has a significant diagnostics presence with global sales in 2015 in this segment of $4.6bn, it forecasts that the acquisition
-
Another lost decade for research?
diseases that cause significant morbidity and mortality, such as influenza and malaria, but remain difficult to vaccinate against.
More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.
Latest appointments
-
Ex-Roche CMO Sandra Horning joins Gilead’s board of directors
During her ten-year career at Roche, Horning helped to bring 15 new medicines to patients in a range of diseases, including cancer, multiple sclerosis, influenza and blindness.
-
Germany's Ventaleon names biotech entrepeneur CEO
patients suffering from serious infections such as influenza to get better, faster.
-
Dr Michael Watson appointed as president of Valera
Dr Watson brings twenty years of vaccines expertise to the role and has broad experience in the development and licensing of vaccines for conditions such as smallpox, encephalitis and influenza.
-
NDA Group appoints Bill Griffiths as general manager, UK
systems teams as well as a specialist influenza vaccines unit.
-
Takeda appoints head of vaccines development
Boslego will be responsible for accelerating global vaccine development activities with a focus on lead development programmes for dengue, norovirus and seasonal influenza.
More from appointments
Approximately 0 fully matching, plus 12 partially matching documents found.
Latest from PMHub
-
Case study
Using qualitative conjoint to assess willingness-to-pay. Find out how we used our proprietary ChoiceQual conjoint technique to assess and develop a market access and pricing strategy for an influenza
-
Fake News is Bad for your Health
Epidemics of measles are occurring across Europe. Rates of vaccination for influenza, HPV, tetanus and polio have also declined.
-
To track disease, follow the money
The way that influenza spreads can be tracked by tools such as Flusurvey,(1) which produces rapidly-updated heatmaps of illness across the country.
-
Influenza
Agency: BASTARD. LONDON. Product: Self Promotion. Client: Self Promotion. Therapy area: Self Promotion. View the PMHub profile for: BASTARD. LONDON.
More from PMHub
Approximately 2 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- FDA hands BMS and bluebird bio a priority review for ide-cel
- BMS eyes approval for second Opdivo combo in kidney cancer
- Pfizer helps fund biotech venture from former researchers at closed Kent facility
- Live Webinar: Leveraging Digital Technologies to Create Valuable KOL Engagements & Empower Patients
- Live Webinar: Harnessing Technology to Improve Health and Healthcare
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- Lilly’s Verzenio scores a win in early-stage breast cancer
- FDA sets January decision date for Xalkori in ALK-positive lymphoma
- Q&A: Isabel Gibson
PMHub
Nucleus Global
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...
Latest intelligence
- Surviving cancer: a new era for patients
- Now more than ever, a shift in perspective is needed...
- Crisis? No problem!
- Issues planning & management for pharma spokespeople, by Andrew Smith...
- Are patient recruitment and retention rates rising or falling?
- First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Quick links
Infographics
